Examples of anti-PD-L1 agents include Atezolizumab, Durvalumab, and Avelumab, which have been approved for treating cancers like urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer [16,17,18]. This evidence concerns the gene CD274 and cancer.